ST. PETERSBURG, Fla., Feb. 21, 2013 /PRNewswire/ — Premier Biomedical, Inc. (OTC-BB: BIEI) today announced that it has acquired exclusive rights to a provisional patent application against Retinitis Pigmentosa. This exclusive intellectual property right, a result of Premier’s long-standing licensing agreements, proposes a novel method for treating the degenerative eye disease via the targeted removal of specified target antigens. This is the latest of many proposed applications of Premier Biomedical, Inc.’s Felder Doctrine. Read more here.
Premier Biomedical, Inc. Announces Potential Therapy For Retinitis Pigmentosa
Posted in News